Oxford BioDynamics (LON:OBD) Stock Price Up 21.4% – Still a Buy?

Oxford BioDynamics Plc (LON:OBD)’s stock price was up 21.4% during trading on Monday . The stock traded as high as GBX 0.30 and last traded at GBX 0.30. 31,979,639 shares were traded during trading, a decline of 10% from the average session volume of 35,485,863 shares. The stock had previously closed at GBX 0.24.

Wall Street Analysts Forecast Growth

Separately, Shore Capital reaffirmed a “house stock” rating on shares of Oxford BioDynamics in a research report on Wednesday, October 8th.

Oxford BioDynamics Price Performance

The business has a fifty day moving average of GBX 0.26 and a two-hundred day moving average of GBX 0.38. The company has a debt-to-equity ratio of 370.22, a quick ratio of 2.80 and a current ratio of 0.68. The firm has a market capitalization of £12.23 million, a price-to-earnings ratio of -0.36 and a beta of 0.42.

Oxford BioDynamics (LON:OBD) last issued its quarterly earnings data on Wednesday, December 24th. The biotechnology company reported GBX (0.80) earnings per share for the quarter. Oxford BioDynamics had a negative net margin of 1,800.32% and a negative return on equity of 289.38%.

About Oxford BioDynamics

Oxford BioDynamics Plc is a global biotechnology company, advancing personalized healthcare by developing and commercializing precision medicine tests for life-changing diseases.

Its flagship product is EpiSwitch® CiRT (Checkpoint Inhibitor Response Test) for cancer, a predictive immune response profile for immuno-oncology (IO) checkpoint inhibitor treatments, launched in February 2022.

In March 2021, the Company launched its first commercial prognostic test, EpiSwitch® CST (Covid Severity Test) and the first commercially available microarray kit for high-resolution 3D genome profiling and biomarker discovery, EpiSwitch® Explorer Array Kit.